Research

facebook twitter google print email
Media Contact:Katie Delach | katie.delach@uphs.upenn.edu | 215-349-5964November 4, 2014

Penn Medicine Studies Show New Evidence that Exercise Therapy, Acupuncture Benefit Breast Cancer Survivors

Two new studies from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania offer

facebook twitter google print email
Media Contact:Lee-Ann Donegan | leeann.donegan@uphs.upenn.edu | 215-349-5660October 30, 2014
facebook twitter google print email
Media Contact:Katherine Unger Baillie | kbaillie@upenn.edu | 215-898-9194October 20, 2014

Penn Physician and Historian Robert Aronowitz Elected to Institute of Medicine

blurb: 
Robert Aronowitz, a physician and historian at the University of Pennsylvania, has been elected to membership in the Institute of Medicine, one of the nation's highest honors in the health-care field.

Robert Aronowitz, a physician and historian at the University of Pennsylvania, has been elected to membership in the Institute of Medicine, one of the nation's highest honors in the health-care field.

facebook twitter google print email
Media Contact:Lee-Ann Donegan | Leeann.donegan@uphs.upenn.edu | 215-349-5660October 20, 2014

Penn Researchers Untangle the Biological Effects of Blue Light

Blue light can both set the mood and set in motion important biological responses.

facebook twitter google print email
Media Contact:Karen Kreeger | karen.kreeger@uphs.upenn.edu | 215-349-5658October 20, 2014

See-Through, One-Atom-Thick, Carbon Electrodes are a Powerful Tool for Studying Epilepsy, Other Brain Disorders, Penn Study Finds

Researchers from the Perelman School of Medicine and 

facebook twitter google print email
Media Contact:Katherine Unger Baillie | kbaillie@upenn.edu | 215-898-9194December 1, 2014

Penn Dental Medicine Welcomes Its First Thouron Scholar

blurb: 
This year, the Thouron Scholars, a community of 700-plus whose disciplines range from geology to English literature, welcomed their very first dentist to the ranks.

By Madeleine Stone  @themadstone

facebook twitter google print email
Media Contact:Katie Delach | katie.delach@uphs.upenn.edu | 215-349-5964October 16, 2014

Penn Medicine Researchers Zero in on Psoriasis-Hypertension Link

Patients with more severe psoriasis are also more likely to have uncontrolled hypertension, according to new research by a team at the Perelman School of Medicine at the University of Pennsylvania

facebook twitter google print email
Media Contact:Katherine Unger Baillie | kbaillie@upenn.edu | 215-898-9194November 11, 2014

Collaborative Penn-Dresden Study Blocks Multiple Sclerosis Relapses in Mice

blurb: 
In a new study, researchers from the University of Pennsylvania and co-investigators have identified a key protein that is able to reduce the severity of a disease equivalent to multiple sclerosis in mice.

In multiple sclerosis, the immune system goes rogue, improperly attacking the body’s own central nervous system. Mobility problems and cognitive impairments may arise as the nerve cells become damaged.

facebook twitter google print email
Media Contact:Anna Duerr | anna.duerr@uphs.upenn.edu | 215-349-8369November 5, 2014

Readmission Rates Above Average for Survivors of Septic Shock, Penn Study Finds

blurb: 
Penn Medicine researchers have now shown that while most patients now survive a hospital stay for septic shock, 23 percent will return to the hospital within 30 days, many with another life-threatening condition -- a rate substantially higher than the normal readmission rate at a large academic medical center.

A diagnosis of septic shock was once a near death sentence. At best, survivors suffered a substantially reduced quality of life.

facebook twitter google print email
Media Contact:Katie Delach | katie.delach@uphs.upenn.edu | 215-349-5964November 6, 2014

Penn Study: Olaparib Shows Promise As Treatment Option for Patients with BRCA-Related Cancers

blurb: 
A Penn Medicine study Finds Olaparib shows success in tumor response rate for patients with BRCA-related cancers. The study's results provide promising treatment option and improved survival rates for patients with ovarian, breast, pancreatic and prostate cancers

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.